Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04347226 · ClinicalTrials.gov registry record · Phase 2
Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19
A Phase 2 study, sponsored by Columbia University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT04347226 is a Phase 2 study that was terminated before completion, run by Columbia University. The registered enrollment target is 43 participants.
The verdict
NCT04347226, a Phase 2 study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
This study is for patients that are hospitalized for Coronavirus Disease 2019 (COVID-19). The purpose of this study is to see whether neutralizing interleukin-8 (IL-8) with BMS-986253 can help improve the health condition of participants infected with COVID-19. This is the first in-human study of this investigational product specifically in patients with severe COVID-19. Currently there are no FDA approved medications that improve the chance of survival in patients diagnosed with COVID-19. However there are usual treatments currently being used to help treat COVID-19 patients and BMS-986253 will be compared to these standard of care treatments in this study.
Interventions
- DRUG BMS-986253
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2020-04-16 |
| Est. Completion | 2021-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04347226
The ClinicalTrials.gov registry entry for NCT04347226 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMS-986253 is the first listed.
NCT04347226 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04347226 about?
NCT04347226 is a clinical study titled "Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19". This study is for patients that are hospitalized for Coronavirus Disease 2019 (COVID-19). The purpose of this study is to see whether neutralizing interleukin-8 (IL-8) with BMS-986253 can help improve the health condition of participants infected with COVID-19. This is the first in-human study of th...
What is the current status of trial NCT04347226?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2020-04-16. Estimated completion is 2021-03-01.
What interventions are being tested in trial NCT04347226?
The interventions under investigation include: BMS-986253 (DRUG).
Who is sponsoring clinical trial NCT04347226?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.